CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond
- 1 February 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 2 (1) , 23-35
- https://doi.org/10.1586/14737140.2.1.23
Abstract
CAMPATH (CAMPATH-1H, alemtuzumab, MabCAMPATH), is a lymphocyte-depleting humanized monoclonal antibody that was recently approved in the USA and Europe for the treatment of chronic lymphocytic leukemia (CLL). It targets CD52--a small glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes and on a large proportion of lymphoid cell malignancies--but not on hematopoietic progenitor cells. CAMPATH was shown to be effective against CLL refractory to chemotherapy with an acceptable toxicity profile. CAMPATH is also active against T-cell prolymphocytic leukemia and has been extensively used to prevent graft-versus-host disease associated with bone marrow transplantation. CAMPATH is owned by ILEX Pharmaceuticals LP and distributed by Schering AG and its US affiliate Berlex Laboratories.Keywords
This publication has 20 references indexed in Scilit:
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- New developments in the prophylaxis and treatment of graft versus host diseaseExpert Opinion on Pharmacotherapy, 2001
- Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyBlood, 2001
- Pharmacokinetics of CAMPATH-1H in BMT patientsCytotherapy, 2001
- Novel treatment strategies in chronic lymphocytic leukemiaCurrent Oncology Reports, 2001
- BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS FOLLOWED BY REPLETION WITH INCREMENTAL DOSES OF DONOR LYMPHOCYTES FOR RELAPSING PATIENTS WITH CHRONIC MYELOID LEUKEMIATransplantation, 2000
- Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosisPublished by Elsevier ,1999
- EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIATransplantation, 1999
- In vivo‘Purging’ of residual disease in CLL with Campath‐1HBritish Journal of Haematology, 1997
- Transient increase in symptoms associated with cytokine release in patients with multiple sclerosisBrain, 1996